PubMed:10364191
Annnotations
CL-cell
| Id | Subject | Object | Predicate | Lexical cue | cl_id |
|---|---|---|---|---|---|
| T1 | 1197-1231 | Cell | denotes | peripheral blood mononuclear cells | http://purl.obolibrary.org/obo/CL:0000842|http://purl.obolibrary.org/obo/CL:2000001 |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-170 | Sentence | denotes | Potent and stable attenuation of live-HIV-1 by gain of a proteolysis-resistant inhibitor of NF-kappaB (IkappaB-alphaS32/36A) and the implications for vaccine development. |
| T2 | 171-294 | Sentence | denotes | Live-attenuated human immunodeficiency viruses (HIVs) are candidates for Acquired Immunodeficiency Syndrome (AIDS) vaccine. |
| T3 | 295-526 | Sentence | denotes | Based on the simian immunodeficiency virus (SIV) model for AIDS, loss-of-function (e.g. deletion of accessory genes such as nef) has been forwarded as a primary approach for creating enfeebled, but replication-competent, HIV-1/SIV. |
| T4 | 527-663 | Sentence | denotes | Regrettably, recent evidence suggests that loss-of-function alone is not always sufficient to prevent the emergence of virulent mutants. |
| T5 | 664-802 | Sentence | denotes | New strategies that attenuate via mechanisms distinct from loss-of-function are needed for enhancing the safety phenotype of viral genome. |
| T6 | 803-927 | Sentence | denotes | Here, we propose gain-of-function to be used simultaneously with loss-of-function as a novel approach for attenuating HIV-1. |
| T7 | 928-1082 | Sentence | denotes | We have constructed an HIV-1 genome carrying the cDNA of a proteolysis-resistant nuclear factor-kappaB inhibitor (IkappaB-alphaS32/36A) in the nef region. |
| T8 | 1083-1232 | Sentence | denotes | HIV-1 expressing IkappaB-alphaS32/36A down-regulates viral expression and is highly attenuated in both Jurkat and peripheral blood mononuclear cells. |
| T9 | 1233-1455 | Sentence | denotes | We provide formal proof that the phenotypic and attenuating characteristics of IkappaB-alphaS32/36A permit its stable maintenance in a live, replicating HIV-1 despite 180 days of forced ex vivo passaging in tissue culture. |
| T10 | 1456-1571 | Sentence | denotes | As compared with other open-reading frames embedded into HIV/SIV genome, this degree of stability is unprecedented. |
| T11 | 1572-1730 | Sentence | denotes | Thus, IkappaB-alphaS32/36A offers proof-of-principle that artifactually gained functions, when used to attenuate the replication of live HIV-1, can be stable. |
| T12 | 1731-1883 | Sentence | denotes | These findings illustrate gain-of-function as a feasible strategy for developing safer live-attenuated HIVs to be tested as candidates for AIDS vaccine. |
Glycosmos6-MAT
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 1208-1213 | http://purl.obolibrary.org/obo/MAT_0000083 | denotes | blood |
| T2 | 1208-1213 | http://purl.obolibrary.org/obo/MAT_0000315 | denotes | blood |
jnlpba-st-training
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 57-88 | protein | denotes | proteolysis-resistant inhibitor |
| T2 | 92-101 | protein | denotes | NF-kappaB |
| T3 | 103-123 | protein | denotes | IkappaB-alphaS32/36A |
| T4 | 419-422 | DNA | denotes | nef |
| T5 | 789-801 | DNA | denotes | viral genome |
| T6 | 951-963 | DNA | denotes | HIV-1 genome |
| T7 | 977-981 | DNA | denotes | cDNA |
| T8 | 987-1040 | protein | denotes | proteolysis-resistant nuclear factor-kappaB inhibitor |
| T9 | 1042-1062 | protein | denotes | IkappaB-alphaS32/36A |
| T10 | 1071-1081 | DNA | denotes | nef region |
| T11 | 1100-1120 | protein | denotes | IkappaB-alphaS32/36A |
| T12 | 1186-1192 | cell_line | denotes | Jurkat |
| T13 | 1197-1231 | cell_type | denotes | peripheral blood mononuclear cells |
| T14 | 1312-1332 | protein | denotes | IkappaB-alphaS32/36A |
| T15 | 1479-1498 | DNA | denotes | open-reading frames |
| T16 | 1513-1527 | DNA | denotes | HIV/SIV genome |
| T17 | 1578-1598 | protein | denotes | IkappaB-alphaS32/36A |
pubmed-sentences-benchmark
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| S1 | 0-170 | Sentence | denotes | Potent and stable attenuation of live-HIV-1 by gain of a proteolysis-resistant inhibitor of NF-kappaB (IkappaB-alphaS32/36A) and the implications for vaccine development. |
| S2 | 171-294 | Sentence | denotes | Live-attenuated human immunodeficiency viruses (HIVs) are candidates for Acquired Immunodeficiency Syndrome (AIDS) vaccine. |
| S3 | 295-526 | Sentence | denotes | Based on the simian immunodeficiency virus (SIV) model for AIDS, loss-of-function (e.g. deletion of accessory genes such as nef) has been forwarded as a primary approach for creating enfeebled, but replication-competent, HIV-1/SIV. |
| S4 | 527-663 | Sentence | denotes | Regrettably, recent evidence suggests that loss-of-function alone is not always sufficient to prevent the emergence of virulent mutants. |
| S5 | 664-802 | Sentence | denotes | New strategies that attenuate via mechanisms distinct from loss-of-function are needed for enhancing the safety phenotype of viral genome. |
| S6 | 803-927 | Sentence | denotes | Here, we propose gain-of-function to be used simultaneously with loss-of-function as a novel approach for attenuating HIV-1. |
| S7 | 928-1082 | Sentence | denotes | We have constructed an HIV-1 genome carrying the cDNA of a proteolysis-resistant nuclear factor-kappaB inhibitor (IkappaB-alphaS32/36A) in the nef region. |
| S8 | 1083-1232 | Sentence | denotes | HIV-1 expressing IkappaB-alphaS32/36A down-regulates viral expression and is highly attenuated in both Jurkat and peripheral blood mononuclear cells. |
| S9 | 1233-1455 | Sentence | denotes | We provide formal proof that the phenotypic and attenuating characteristics of IkappaB-alphaS32/36A permit its stable maintenance in a live, replicating HIV-1 despite 180 days of forced ex vivo passaging in tissue culture. |
| S10 | 1456-1571 | Sentence | denotes | As compared with other open-reading frames embedded into HIV/SIV genome, this degree of stability is unprecedented. |
| S11 | 1572-1730 | Sentence | denotes | Thus, IkappaB-alphaS32/36A offers proof-of-principle that artifactually gained functions, when used to attenuate the replication of live HIV-1, can be stable. |
| S12 | 1731-1883 | Sentence | denotes | These findings illustrate gain-of-function as a feasible strategy for developing safer live-attenuated HIVs to be tested as candidates for AIDS vaccine. |
genia-medco-coref
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| C1 | 33-43 | NP | denotes | live-HIV-1 |
| C2 | 55-124 | NP | denotes | a proteolysis-resistant inhibitor of NF-kappaB (IkappaB-alphaS32/36A) |
| C3 | 244-293 | NP | denotes | Acquired Immunodeficiency Syndrome (AIDS) vaccine |
| C4 | 360-423 | NP | denotes | loss-of-function (e.g. deletion of accessory genes such as nef) |
| C5 | 570-592 | NP | denotes | loss-of-function alone |
| C6 | 664-678 | NP | denotes | New strategies |
| C7 | 679-683 | NP | denotes | that |
| C8 | 723-739 | NP | denotes | loss-of-function |
| C9 | 820-836 | NP | denotes | gain-of-function |
| C10 | 868-884 | NP | denotes | loss-of-function |
| C11 | 985-1063 | NP | denotes | a proteolysis-resistant nuclear factor-kappaB inhibitor (IkappaB-alphaS32/36A) |
| C12 | 1244-1256 | NP | denotes | formal proof |
| C13 | 1257-1261 | NP | denotes | that |
| C14 | 1312-1332 | NP | denotes | IkappaB-alphaS32/36A |
| C15 | 1340-1343 | NP | denotes | its |
| C16 | 1578-1598 | NP | denotes | IkappaB-alphaS32/36A |
| C17 | 1606-1624 | NP | denotes | proof-of-principle |
| C18 | 1625-1629 | NP | denotes | that |
| C19 | 1704-1714 | NP | denotes | live HIV-1 |
| C20 | 1757-1773 | NP | denotes | gain-of-function |
| C21 | 1870-1882 | NP | denotes | AIDS vaccine |
| R1 | C5 | C4 | coref-ident | loss-of-function alone,loss-of-function (e.g. deletion of accessory genes such as nef) |
| R2 | C7 | C6 | coref-relat | that,New strategies |
| R3 | C8 | C5 | coref-ident | loss-of-function,loss-of-function alone |
| R4 | C10 | C8 | coref-ident | loss-of-function,loss-of-function |
| R5 | C11 | C2 | coref-ident | a proteolysis-resistant nuclear factor-kappaB inhibitor (IkappaB-alphaS32/36A),a proteolysis-resistant inhibitor of NF-kappaB (IkappaB-alphaS32/36A) |
| R6 | C13 | C12 | coref-relat | that,formal proof |
| R7 | C14 | C11 | coref-ident | IkappaB-alphaS32/36A,a proteolysis-resistant nuclear factor-kappaB inhibitor (IkappaB-alphaS32/36A) |
| R8 | C15 | C14 | coref-pron | its,IkappaB-alphaS32/36A |
| R9 | C16 | C14 | coref-ident | IkappaB-alphaS32/36A,IkappaB-alphaS32/36A |
| R10 | C18 | C17 | coref-relat | that,proof-of-principle |
| R11 | C19 | C1 | coref-ident | live HIV-1,live-HIV-1 |
| R12 | C20 | C9 | coref-ident | gain-of-function,gain-of-function |
| R13 | C21 | C3 | coref-ident | AIDS vaccine,Acquired Immunodeficiency Syndrome (AIDS) vaccine |
GENIAcorpus
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 33-43 | virus | denotes | live-HIV-1 |
| T2 | 57-88 | protein_family_or_group | denotes | proteolysis-resistant inhibitor |
| T3 | 92-101 | protein_complex | denotes | NF-kappaB |
| T4 | 103-123 | protein_molecule | denotes | IkappaB-alphaS32/36A |
| T5 | 150-169 | other_name | denotes | vaccine development |
| T6 | 171-217 | virus | denotes | Live-attenuated human immunodeficiency viruses |
| T7 | 219-223 | virus | denotes | HIVs |
| T8 | 244-293 | other_name | denotes | Acquired Immunodeficiency Syndrome (AIDS) vaccine |
| T9 | 308-349 | virus | denotes | simian immunodeficiency virus (SIV) model |
| T10 | 354-358 | other_name | denotes | AIDS |
| T11 | 360-376 | other_name | denotes | loss-of-function |
| T12 | 419-422 | DNA_domain_or_region | denotes | nef |
| T13 | 516-525 | virus | denotes | HIV-1/SIV |
| T14 | 570-586 | other_name | denotes | loss-of-function |
| T15 | 646-662 | virus | denotes | virulent mutants |
| T16 | 723-739 | other_name | denotes | loss-of-function |
| T17 | 789-801 | DNA_family_or_group | denotes | viral genome |
| T18 | 820-836 | other_name | denotes | gain-of-function |
| T19 | 868-884 | other_name | denotes | loss-of-function |
| T20 | 921-926 | virus | denotes | HIV-1 |
| T21 | 951-956 | virus | denotes | HIV-1 |
| T22 | 977-981 | DNA_family_or_group | denotes | cDNA |
| T23 | 987-1040 | protein_family_or_group | denotes | proteolysis-resistant nuclear factor-kappaB inhibitor |
| T24 | 1042-1062 | protein_molecule | denotes | IkappaB-alphaS32/36A |
| T25 | 1071-1074 | DNA_domain_or_region | denotes | nef |
| T26 | 1083-1088 | virus | denotes | HIV-1 |
| T27 | 1100-1120 | protein_molecule | denotes | IkappaB-alphaS32/36A |
| T28 | 1136-1152 | other_name | denotes | viral expression |
| T29 | 1186-1192 | cell_line | denotes | Jurkat |
| T30 | 1197-1231 | cell_type | denotes | peripheral blood mononuclear cells |
| T31 | 1312-1332 | protein_molecule | denotes | IkappaB-alphaS32/36A |
| T32 | 1386-1391 | virus | denotes | HIV-1 |
| T33 | 1440-1454 | other_artificial_source | denotes | tissue culture |
| T34 | 1479-1498 | DNA_family_or_group | denotes | open-reading frames |
| T35 | 1513-1527 | DNA_family_or_group | denotes | HIV/SIV genome |
| T36 | 1578-1598 | protein_molecule | denotes | IkappaB-alphaS32/36A |
| T37 | 1704-1708 | virus | denotes | live |
| T38 | 1709-1714 | virus | denotes | HIV-1 |
| T39 | 1757-1773 | other_name | denotes | gain-of-function |
| T40 | 1818-1833 | virus | denotes | live-attenuated |
| T41 | 1834-1838 | virus | denotes | HIVs |
| T42 | 1870-1882 | other_name | denotes | AIDS vaccine |
PubmedHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 193-209 | HP_0002721 | denotes | immunodeficiency |
| T2 | 253-269 | HP_0002721 | denotes | Immunodeficiency |
| T3 | 315-331 | HP_0002721 | denotes | immunodeficiency |
HP-phenotype
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 193-209 | Phenotype | denotes | immunodeficiency | HP:0002721 |
| T2 | 253-269 | Phenotype | denotes | Immunodeficiency | HP:0002721 |
| T3 | 315-331 | Phenotype | denotes | immunodeficiency | HP:0002721 |
mondo_disease
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 193-209 | Disease | denotes | immunodeficiency | http://purl.obolibrary.org/obo/MONDO_0021094 |
| T2 | 244-278 | Disease | denotes | Acquired Immunodeficiency Syndrome | http://purl.obolibrary.org/obo/MONDO_0012268 |
| T3 | 280-284 | Disease | denotes | AIDS | http://purl.obolibrary.org/obo/MONDO_0012268 |
| T4 | 315-331 | Disease | denotes | immunodeficiency | http://purl.obolibrary.org/obo/MONDO_0021094 |
| T5 | 339-342 | Disease | denotes | SIV | http://purl.obolibrary.org/obo/MONDO_0010029 |
| T6 | 354-358 | Disease | denotes | AIDS | http://purl.obolibrary.org/obo/MONDO_0012268 |
| T7 | 522-525 | Disease | denotes | SIV | http://purl.obolibrary.org/obo/MONDO_0010029 |
| T8 | 1517-1520 | Disease | denotes | SIV | http://purl.obolibrary.org/obo/MONDO_0010029 |
| T9 | 1870-1874 | Disease | denotes | AIDS | http://purl.obolibrary.org/obo/MONDO_0012268 |
NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 187-192 | OrganismTaxon | denotes | human | 9606 |
| T2 | 308-337 | OrganismTaxon | denotes | simian immunodeficiency virus | 11723 |
| T3 | 339-342 | OrganismTaxon | denotes | SIV | 11723 |
| T4 | 522-525 | OrganismTaxon | denotes | SIV | 11723 |
| T5 | 1517-1520 | OrganismTaxon | denotes | SIV | 11723 |
Anatomy-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 1197-1231 | Body_part | denotes | peripheral blood mononuclear cells | http://purl.obolibrary.org/obo/CL_0000842|http://purl.obolibrary.org/obo/CL_2000001 |
| T3 | 1440-1446 | Body_part | denotes | tissue | http://purl.obolibrary.org/obo/UBERON_0000479 |
Anatomy-MAT
| Id | Subject | Object | Predicate | Lexical cue | mat_id |
|---|---|---|---|---|---|
| T1 | 1208-1213 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/MAT_0000083|http://purl.obolibrary.org/obo/MAT_0000315 |